Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Experience with Eslicarbazepine in the IDD/Long-Term Care Epilepsy Population
Epilepsy/Clinical Neurophysiology (EEG)
P9 - Poster Session 9 (12:00 PM-1:00 PM)
12-005
This retrospective chart review was performed to study eslicarbazepine acetate (ESL) in epilepsy patients with intellectual and developmental disabilities (IDD) in long-term care settings.  In addition, the transition of patients from carbamazepine (CBZ) to ESL was analyzed.
As the experience of ESL is demonstrated in clinical practice, a literature review yields little information regarding use in the IDD/long-term care epilepsy population.  Challenges exist in this group including a higher incidence of refractory epilepsy, multiple comorbidities, and polypharmacy.  There are also questions about the transition of patients from CBZ to ESL.
The charts of all 32 IDD patients started on ESL in a private epilepsy practice were reviewed.  Seizure frequency, related hospital/ER visits, and side effects for 6 months before and after starting ESL were collected.  Seizure free patients were followed at 6 and 12 months while retention was measured at 6, 12, 24, and 36 months.  CBZ to ESL transition was also studied.
13/22 patients had a 50-100% reduction in seizures.  7/22 patients reported no change.  2/22 patients had a 1-49% reduction in seizures.  18/22 patients had no hospital or ER visits for seizures.  4/22 patients had a reduction in ER visits.  4/32 patients reported adverse effects:  3 had nausea and vomiting (1 stopped ESL) and 1 reported worsening of mood.  Seizure freedom occurred in 5/22 patients at 6 months and 3/16 at 12 months.  Retention of ESL was 29/30 patients at 6 months, 25/27 at 12 months, 15/15 at 24 months, and 13/13 at 36 months.  6/7 patients reported no adverse effects with transition from CBZ to ESL although one reported worsening of mood.
The use of ESL in IDD/Long Term Care epilepsy patients appears well tolerated and efficacious as well as the transition from CBZ to ESL.
Authors/Disclosures
Jess Collins, MD (Baylor Scott & White Cancer Center Round Rock)
PRESENTER 		No disclosure on file